Endogenously Expressed IL-13Rα2 Attenuates IL-13–Mediated Responses but Does Not Activate Signaling in Human Lung Fibroblasts
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
IL-13 can bind to two distinct receptors: a heterodimer of IL-13Rα1/IL-4Rα and IL-13Rα2. Whereas IL-13Rα1/IL-4Rα engagement by IL-13 leads to the activation of STAT6, the molecular events triggered by IL-13 binding to IL-13Rα2 remain incompletely understood. IL-4 can bind to and signal through the IL-13Rα1/IL-4Rα complex but does not interact with IL-13Rα2. Idiopathic pulmonary fibrosis is a progressive and generally fatal parenchymal lung disease of unknown etiology with no current pharmacologic treatment options that substantially prolong survival. Preclinical models of fibrotic diseases have implicated IL-13 activity on multiple cell types, including macrophages and fibroblasts, in initiating and perpetuating pathological fibrosis. In this study, we show that IL-13, IL-4, IL-13Rα2, and IL-13–inducible target genes are expressed at significantly elevated levels in lung tissue from patients with idiopathic pulmonary fibrosis compared with control lung tissue. IL-4 and IL-13 induce virtually identical transcriptional responses in human monocytes, macrophages, and lung fibroblasts. IL-13Rα2 expression can be induced in lung fibroblasts by IL-4 or IL-13 via a STAT6-dependent mechanism, or by TNF-α via a STAT6-independent mechanism. Endogenously expressed IL-13Rα2 decreases, but does not abolish, sensitivity of lung fibroblasts to IL-13 and does not affect sensitivity to IL-4. Genome-wide transcriptional analyses of lung fibroblasts stimulated with IL-13 in the presence of Abs that selectively block interactions of IL-13 with IL-13Rα1/IL-4Rα or IL-13Rα2 show that endogenously expressed IL-13Rα2 does not activate any unique IL-13–mediated gene expression patterns, confirming its role as a decoy receptor for IL-13 signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940
Woodruff, P. G., Boushey, H. A., Dolganov, G. M., Barker, C. S., Yang, Y. H., Donnelly, S., Ellwanger, A., Sidhu, S. S., Dao-Pick, T. P., Pantoja, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707413104 · Cited by 828 · cited 9×
“STAT6 knockdown decreased IL-13–mediated induction of known IL-13–responsive genes periostin and CCL26 (39, 40), whereas TNF-a did not induce periostin or CCL26 expression (Fig.”
BackgroundInfluentialChiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603 · cited 1×
“fibrosis whereas IL-13Ra1–deficient animals exhibit decreased tissue fibrosis (13, 26, 27).”
BackgroundSong, E., Ouyang, N., Hörbelt, M., Antus, B., Wang, M., & Exton, M. S. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1687 · Cited by 447
Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab
Ultsch, M., Bevers, J., Nakamura, G., Vandlen, R., Kelley, R. F., Wu, L. C., & Eigenbrot, C. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.01.024 · Cited by 174
Self-citation
Cited by
Commentary: IL-4 and IL-13 receptors and signaling
McCormick, S. M., & Heller, N. M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.023 · Cited by 317
Popovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., Spooner, J., Keen, J., Minter, R., Uddin, F., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.005 · Cited by 198
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
Gieseck, R. L., Ramalingam, T. R., Hart, K. M., Vannella, K. M., Cantu, D. A., Lu, W.-Y., Ferreira-González, S., Forbes, S. J., Vallier, L., & Wynn, T. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.009 · Cited by 132
Weng, S.-Y., Wang, X., Vijayan, S., Tang, Y., Kim, Y. O., Padberg, K., Regen, T., Molokanova, O., Chen, T., Bopp, T., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.028 · Cited by 128
“…to its anti-inflammatory and fibrolytic role during regression, relativates prior results with IL-4, IL-13 or IL-13Rα2 in the models of pulmonary (Chandriani et al., 2014), (Schistosomal) liver (Cheever et al., 1994; Chiaramonte et al., 1999; Kaviratne et al., 2004) and intestinal fibrosis…”
BackgroundResultInfluential
Metadata
- Authors
- Chandriani, S., DePianto, D. J., N’Diaye, E. N., Abbas, A. R., Jackman, J., Bevers, J., Ramirez-Carrozzi, V., Pappu, R., Kauder, S. E., Toy, K., Ha, C., Modrusan, Z., Wu, L. C., Collard, H. R., Wolters, P. J., Egen, J. G., & Arron, J. R.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-01
- Volume
- 193
- Issue
- 1
- Pages
- 111-119
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1676154821
- Cited by
- 63
- References
- 7
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.